Oct. 22.-25. 2016
Gürzenich, Cologne
P026 (P026) Hodgkin cell-derived extracellular vesicles shape fibroblast activity
P030 (P030) The lymphoid cell specific transcription factor ELF-1 is transcriptionally downregulated and recurrently deleted in classical Hodgkin lymphoma (cHL)
P036 (P036) Tightly regulated FOXO3 expression is critical for the maintenance of cHL
T004 (T004) Analysis of the mutational landscape and dynamics in Hodgkin Lymphoma using NGS
T005 (T005) High expression of programmed cell death receptor 1 (PD-1) in the tumor microenvironment is associated with inferior event free survival in classical Hodgkin Lymphoma
T006 (T006) The AP-1 transcription factor BATF3 regulates MYC expression and is required for tumor cell survival in classical Hodgkin Lymphoma and anaplastic large cell lymphoma
P024 (P024) Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma
P025 (P025) Determination of the mutational landscape of primary Hodgkin and Reed/Sternberg cells of classical Hodgkin lymphoma
P027 (P027) Prognostic implications of an active, innate or anergic immune response in the Hodgkin lymphoma tumor microenvironment
P028 (P028) Studying the role of oncogenic miR-24-3p in Hodgkin lymphoma
P029 (P029) Characterization of Hodgkin lymphoma clonogenic cells using a new L428 in vivo xenograft model in immunodeficient NOD/SCID-gammac-/- mice and peripheral lymphocytes study in Hodgkin Lymphoma patients
P031 (P031) Mutations in CD58 and MYB in Hodgkin lymphoma
P032 (P032) Re-fusion of small mononucleated Hodgkin cells leads to giant multinucleated Reed-Sternberg cells in Hodgkin lymphoma
P033 (P033) Molecular characterization of Bruton’s Tyrosine Kinase Inhibitor in Hodgkin’s Lymphoma: Cellular and Animal Models
P034 (P034) Functional analysis to elucidate the susceptibility mechanisms of SNPs at the REL, GATA3 and TCF3 loci in classical Hodgkin Lymphoma
P035 (P035) IGH-mediated translocations, recurrent in classic Hodgkin lymphoma, frequently correlate with an aggressive behavior
P037 (P037) In-Vitro and In-Vivo preclinical activity of EDO-S101 in Hodgkin lymphoma
P038 (P038) Hodgkin Reed-Sternberg cells in classical Hodgkin lymphoma are surrounded by T regulatory cells while lymphocyte predominant cells of nodular lymphocyte predominant Hodgkin lymphoma are surrounded by T follicular helper cells
P039 (P039) The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients exposed for granulocyte-colony stimulating growth factor
P040 (P040) Correlation between pre-treatment level of soluble PD-L1 and outcome in classical Hodgkin lymphoma included in a prospective study of the Lymphoma Study Association (LYSA)
P041 (P041) Proteasome Inhibitor Therapy (PIT) in Hodgkin Lymphoma (HL): Leveraging Systems Biology Analyses (SBA) for Cell-Specific Transcriptome Alterations and Optimum Combinatorial Therapy
P042 (P042) Telomere maintenance mechanisms and Tumor microenvironment are key factors in the outcome of classic Hodgkin lymphoma
P043 (P043) Phenotypic characterization of circulating lymphocytes in Hodgkin´s lymphoma (HL) with focus on T cells
P044 (P044) SIP-F1: A new gray zone lymphoma cell line?
P045 (P045) CD4 lymphopenia as a prognosis factor in previously untreated Hodgkin lymphoma
P046 (P046) Can plasma chemokines and soluble receptor monitoring predict outcome in classical Hodgkin’s Lymphoma (cHL) patients?
P047 (P047) Expression and prognostic impact of indoleamine 2,3-dioxygenase in Hodgkin’s lymphoma
P048 (P048) Reed-Sternberg Cells on Bone Marrow Cytology: The Very Early Feature on Hemophagocytic Lymphohistiocytosis Associated to Hodgkin Lymphoma
P048B (P048B) A novel PTPN1 splice variant regulates JAK/STAT activity in classical Hodgkin’s lymphoma cells
T010 (T010) Long-term follow-up of contemporary treatment in early-stage favorable Hodgkin Lymphoma (HL): updated analyses of the German Hodgkin Study Group HD7 and HD10 trial
T012 (T012) Results of US intergroup trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for non-bulky stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)
P049 (P049) Long-Term Follow-Up of Contemporary Treatment in Early-Stage Unfavorable Hodgkin Lymphoma (HL): Updated Analyses of the German Hodgkin Study Group HD8 and HD11 Trial
P050 (P050) Final Results of a Quality Assurance Program within the German Hodgkin Study Group HD13/14 trial – A report from the radiotherapy reference panel integrating modern guidelines
P051 (P051) Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD x 2 cycles followed by PET/CT restaging and 20 Gy of involved-site radiotherapy
P052 (P052) Optimized “butterfly” VMAT reduces mean dose to coronary arteries for early stage HL patients undergoing mediastinal radiotherapy
P053 (P053) Biological evaluation in the treatment planning. Is there a use for patients with Hodgkin’s Lymphoma?
P054 (P054) The effect of deep inspiration breath hold (DIBH) Intensity-Modulated Radiation Therapy (IMRT) on sparing healthy tissues in the treatment of lymphoma involving the mediastinum
P055 (P055) Multicentric Italian Experience in Treatment of Nodular Lymphocyte Predominant Hodgkin lymphoma (NLPHL) in the Rituximab Era
P056 (P056) Construction of a Decision Model to Aid Treatment Choices for Early Stage Hodgkin Lymphoma (ES HL): Bringing Survivorship Forward
P057 (P057) Doses to organs at risk at different modes of 3D-conformal radiotherapy for mediastinal stage II Hodgkin Lymphoma (HL)
P058 (P058) Residual site radiation therapy (RS RT): An opportunity to increase safety of combined modality therapy (CMT) for early stage Hodgkin lymphoma (HL)
T011 (T011) Proton radiotherapy for mediastinal Hodgkin Lymphoma: single institution experience
T001 (T001) BEACOPP escalated followed by radiotherapy of initial bulk or residual disease in advanced-stage Hodgkin Lymphoma: long-term follow-up of the GHSG HD9 and HD12 trials
T002 (T002) Overall survival (OS) impact of BEACOPP versus ABVD in advanced Hodgkin Lymphoma: a pooled analysis of 4 randomized trials
T003 (T003) Long-term follow-up of SWOG S0816: response-adapted therapy of advanced stage Hodgkin Lymphoma using early interim FDG-PET imaging
P001 (P001) Sequential Brentuximab Vedotin (BV) and Adriamycin, Vinblastine, and Dacarbazine (AVD) for Older Patients with Untreated Hodgkin Lymphoma (HL): Findings from a Phase II Window Study
P002 (P002) Preliminary results of a phase II study of brentuximab vedotin using a response adapted design in the first line treatment of patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity (BREVITY)
P004 (P004) Gray Zone Lymphoma (GZL) with Features Intermediate Between Diffuse Large B-cell Lymphoma (DLBCL) and classical Hodgkin lymphoma (cHL): Diagnostic Experiences and Challenges from a Multicenter Study
P005 (P005) Hodgkin lymphoma in Sweden since 2000: better survival only in elderly women – a Swedish Lymphoma Registry study
P006 (P006) Advanced Hodgkin Lymphoma in the East of England Cancer Network: A 10 year comparative analysis of outcomes for ABVD and escalated BEACOPP treated patients aged 16–59
P007 (P007) Superiority of Modified Progression Free Survival (mPFS) to Evaluate Chemotherapy Effectiveness for Advanced Stage Hodgkin Lymphoma
P008 (P008) Treatment results for Hodgkin Lymphoma in Brazil: first report from the Brazilian Prospective Hodgkin’s Lymphoma Registry
P009 (P009) Dose-Dense/Dose-Intense ABVD (dd-di ABVD) in advanced stage Hodgkin's Lymphoma (HL): A Long-Term Follow Up Study
P010 (P010) THE SWITCH FROM ABVD TO eBEACOPP AS FRONT-LINE THERAPY FOR HIGH-RISK STAGE III-IV CLASSICAL HODGKIN LYMPHOMA (cHL) PATIENTS RESULTS IN AN INVERSION OF EVENT-FREE SURVIVAL (EFS) OF PROGNOSTIC GROUPS
P011 (P011) HALO Study: a phase 1/2 clinical trial of Brentuximab-Vedotin and Bendamustin in elderly patients with previously untreated advanced hodgkin lymphoma. Preliminary data
P012 (P012) Transformation of nodular Hodgkin's lymphoma with lymphocyte predominance to T-cell-rich large B-cell lymphoma
P013 (P013) ABVD AS THE TREATMENT OPTION IN HODGKIN LYMPHOMA WITH LARGE MEDIASTINAL TUMOR
P014 (P014) PERIPHERAL BLOOD EOSINOPHILIA IS A GOOD RISK FACTOR IN POOR PROGNOSIS GROUP: ADVANCED HODGKIN LYMPHOMA WITH LOW ALC/AMC
P015 (P015) Lower socioeconomic status is associated with shorter survival in HL patients – an analysis from the Brazilian Hodgkin Lymphoma Registry
P016 (P016) THE IMPACT OF OUTCOME OF INTERIM PET/CT ON ADVANCED HODGKIN LYMPHOMA TREATED WITH BEACOPP-14
P017 (P017) ADVANCED HODGKIN LYMPHOMA – A RISK STRATIFICATION OF ABVD TREATED FEMALES IN GENERATIVE AGE
P018 (P018) ADVANCED STAGE HODGKIN LYMPHOMA IN MOROCCAN ADULTS: CLINICO-PATHOLOGICAL FEATURES AND THERAPEITIC OUTCOMES
P019 (P019) General population-derived specific survival applied to Hodgkin Lymphoma
P020 (P020) The diagnostics and therapy of Hodgkin lymphoma in pregnancy, the experiences of one center
P021 (P021) Difficulties in distinguishing syncytial variant of nodular sclerosis classical Hodgkin’s lymphoma from diffuse large B-cell lymphoma and complete remission after intensive chemotherapy
P022 (P022) Systemic Hodgkin's Disease with osseal involvement
P023 (P023) Brentuximab Vedotin Alone and in Combination With Dacarbazine or Bendamustine in Patients Aged ≥60 Years With Newly Diagnosed Hodgkin Lymphoma: Interim Results of a Phase 2 Study
T007 (T007) Hodgkin Lymphoma infiltrating T cells: considering various means of tumor evasion
T008 (T008) CCR5 blocking by Maraviroc inhibited recruitment, proliferation and pro-tumor effects of mesenchymal stromal cells and monocytes in 2D and 3D models of Hodgkin Lymphoma microenvironment
T009 (T009) Disturbed antigen presentation in classical Hodgkin Lymphoma: implications for immune checkpoint inhibitor therapy?
T013 (T013) Plasma vesicle-associated miRNAs as therapy response biomarkers in Hodgkin Lymphoma
T014 (T014) Mid-treatment TARC and mid-treatment FDG-PET predict for progression free survival in classical Hodgkin Lymphoma
T015 (T015) A comprehensive analysis of Hodgkin Lymphoma seasonality across various geographic regions
P060 (P060) Evaluation of Serum TARC Levels in Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma: Results from the AETHERA Trial
P061 (P061) Validation of a clinical/biological prognostic model in a large cohort of elderly patients with a classical Hodgkin lymphoma
P062 (P062) Outcomes and prognostic factors in Hodgkin lymphoma – a single center experience
P063 (P063) Combined prognostic role of TARC protein and PET/CT in patients with Hodgkin lymphoma
P065 (P065) Joint pediatric Hodgkin and Non-Hodgkin lymphoma study group on grey zone lymphoma in children and adolescents
T016 (T016) Whole body functional and anatomical MRI: accuracy in staging and treatment response monitoring in childhood and adolescent Hodgkin’s Lymphoma compared to conventional multimodality imaging (CRUK C23580/A12707)
T017 (T017) Phase III study of response adapted therapy for the treatment of children with newly diagnosed very high risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): a report from the Children’s Oncology Group
T018 (T018) Outcomes in adolescents and young adults (AYA) with Hodgkin Lymphoma (HL) treated on US cooperative group protocols: an adult intergroup (E2496) and Children’s Oncology Group (COG AHOD0031) comparative analysis
P066 (P066) Hodgkin lymphoma in children, adolescents and young adults – a comparative study of clinical presentation and treatment outcome
P067 (P067) Pharmacokinetics, Immunogenicity and Safety of Weekly Dosing of Brentuximab Vedotin in Pediatric Patients with Hodgkin Lymphoma
P068 (P068) Approach and Feasibility of Patient-Reported Outcomes (PROs) in a Phase III clinical trial for advanced stage classical Hodgkin Lymphoma (cHL) in children and adolescents
P069 (P069) Prediction of primary treatment response and outcome in pediatric Hodgkin lymphoma using digital gene expression profiling
P070 (P070) Does involved field radiotherapy improve survival rates in pediatric Classic Hodgkin’s Lymphoma?: A retrospective study of 694 children
P071 (P071) CHIPS as a Predictor of Outcome in Radiated vs. Unradiated HL
P073 (P073) Hodgkin lymphoma (HL) in AYA (adolescents and young adults): Results from a single-tertiary-center prospective cohort of 349 patients
P074 (P074) Prognostic value of ‘interim’ positron emission tomography among children with Advanced Hodgkin lymphoma in developing countries; Children Cancer Hospital Egypt experience
P075 (P075) Long-lasting remission in an adolescent with refractory Hodgkin lymphoma after brentuximab vedotin-containing treatment – a case report
P076 (P076) Overview and Survival of Pediatric Advanced stage Hodgkin Lymphoma treated in Developing countries; Children Cancer Hospital Egypt Experience
T019 (T019) Only focal bone marrow FDG uptake in baseline FDG-PET scan has a diagnostic and prognostic impact in Hodgkin Lymphoma: results from an international collaborative study
T020 (T020) Strong predictive value of PET based metabolic tumor volume on survival after autologous HCT for Hodgkin Lymphoma
T021 (T021) Semi-quantitative parameters to improve the interim FDG-PET/CT positive predictive value in Hodgkin Lymphoma
P077 (P077) The importance of bone marrow 18F-FDG uptake and focal skeletal lesions on survival in patients with newly diagnosed Hodgkin lymphoma
P078 (P078) INTERIM PET POSITIVITY IN HODGKIN LYMPHOMA: CLINICAL FEATURES AND OUTCOMES
P079 (P079) Is FDG-PET the most sensitive tool to diagnose bleomycin induced pneumonitis in Hodgkin’s lymphoma?
T022 (T022) CheckMate 205 cohort C: Nivolumab in patients with classical Hodgkin Lymphoma after prior Brentuximab Vedotin and autologous hematopoietic stem cell transplantation
T023 (T023) Pembrolizumab for relapsed/refractory classical Hodgkin Lymphoma (R/R cHL): Multicohort, phase 2 KEYNOTE-087 study
T024 (T024) TRANSPLANT BRaVE: combining Brentuximab Vedotin with DHAP as salvage treatment in relapsed/refractory Hodgkin Lymphoma (HL). A phase 1 dose-escalation study
P080 (P080) A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412)
P081 (P081) Benefit of tandem stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma patients: A French prospective multicenter observational study on 120 patients
P082 (P082) Brentuximab Vedotin Plus Bendamustine as a Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma
P083 (P083) PET adapted dose escalation of brentuximab vedotin as first line salvage therapy in relapse/refractory HL
P084 (P084) Very Late Relapse (VLR) >5 Years after First Diagnosis of Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group HD7-HD12 Trials
P085 (P085) An International Multicenter Phase I/II Study of Brentuximab Vedotin (BV) and Bendamustine (B) in Patients with Heavily Treated Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL) Demonstrates Marked Durable Respon
P086 (P086) Post transplant outcomes in a multicenter phase II study of brentuximab vedotin as first line salvage therapy in relapsed or refractory HL prior to ASCT
P087 (P087) T cell replete Haploidentical transplantation with post-infusion cyclophosphamide in poor prognosis Hodgkin lymphoma
P088 (P088) PET-adapted therapy with Brentuximab vedotin (BV) and Augmented ICE for relapsed/refractory Hodgkin lymphoma – Lack of improvement with 3 versus 2 cycles of weekly BV
P089 (P089) Brentuximab vedotin after autologous stem cell transplant (ASCT) yields the strongest benefit in Hodgkin lymphoma (HL) patients with ≥ 2 risk factors: results of a multivariate analysis (MVA)
P090 (P090) Nivolumab Re-treatment in Patients With Relapsed/Refractory Hodgkin Lymphoma: Safety and Efficacy Outcomes From a Phase 1 Clinical Trial
P092 (P092) Complete Responses to Immune Checkpoint Inhibitors in Patients with Relapsed or Refractory Hodgkin Lymphoma Previously Treated with 5-Azacitidine: A Possible Role for Epigenetic Priming?
P093 (P093) Brentuximab Vedotin (BV) in Patients who are Ineligible for Autologous Stem Cell Transplant (ASCT) with Relapsed or Refractory Hodgkin Lymphoma (rrHL): A UK and Germany Retrospective Study
P094 (P094) Real-World Effectiveness of Brentuximab Vedotin (BV) vs. Other Treatments in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL) post Autologous Stem-Cell Transplantation (ASCT)
P095 (P095) Risk Factors (RFs) for Relapse in Patients with Relapsed or Refractory Hodgkin Lymphoma (rrHL) after Autologous Stem Cell Transplant (ASCT): A Real-World Analysis in Germany and the United Kingdom (UK)
P096 (P096) VERY LATE RELAPSES (VLRs) OCCURING AT LEAST 5 YEARS AFTER THE INITIATION OF TREATMENT WITH CHEMOTHERAPY (CT) OR COMBINED MODALITY THERAPY (CMT) IN PATIENTS WITH HODGKIN (HL): INCIDENCE, RISK FACTORS AND OUTCOME
P097 (P097) Long-term outcome of reduced-intensity allogeneic transplant in relapsed/refractory Hodgkin’s lymphoma: the timing of relapse after autologous transplant and primary refractory disease do not impact the long-term survival
P098 (P098) The Pharmacokinetic and Pharmacodynamic Properties of Brentuximab Vedotin in a Patient Undergoing Hemodialysis
P099 (P099) Immune Systems Engagement Results in Non-Classical Antibody-Drug Conjugate Antitumor Activity of Brentuximab Vedotin
P100 (P100) The long-term outcome of patients with classical Hodgkin Lymphoma (HL) and negative interim PET (iPET) failing ABVD might be worse than that of iPET positive patients undergoing early treatment intensification with escalated BEACOPP
P101 (P101) The value of Brentuximab Vedotin in relapsed/refractory Hodgkin lymphoma patients based on pooled-analysis
P102 (P102) A role for allogeneic stem cell transplantation in the era of novel agents for Hodgkin's lymphoma?
P103 (P103) Salvage Treatments for Relapsed Classical Hodgkin Lymphoma in Children and Adolescents: a 10-Year Experience in a Single Centre
P104 (P104) Single-arm study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma (RRHL) who are ineligible for stem cell transplantation (SCT) or multiagent chemotherapy
P105 (P105) Outcome of very late relapse in Hodgkin lymphoma – a report from Debrecen, Hungary
P106 (P106) LIMITED EFFICACY OF BRENTUXIMAB VEDOTIN (BV) IN A HEAVILY PRE-TREATED HODGKIN LYMPHOMA (HL) POPULATION
P107 (P107) The role of stem cell transplantation (SCT) in Hodgkin’s disease; perspectives from retrospective analysis
P108 (P108) Autologous Stem cell transplantation in Hodgkin Lymphoma: experience of two centers in Brazil
P109 (P109) PD1-Inhibition with Nivolumab after Allogeneic Haematopoietic Cell Transplantation for Hodgkin’s Lymphoma
P110 (P110) Efficacy of Brentuximab Vedotin in the treatment of relapsed Hodgkin Lymphoma and concomitant Mycosis Fungoides
P111 (P111) Programmed Death 1 Blockade with Nivolumab as Salvage Therapy for Heavily Pre-treated Classical Hodgkin’s Lymphoma Relapsing after Allogeneic Stem Cell Transplantation: A Case Report
P112 (P112) Major response of heavily pretreated Hodgkin lymphoma to Nivolumab: The immune system reloaded
P113 (P113) Treatment of a Patient with Primary Refractory Hodgkin Lymphoma and Concurrent Central Nervous System Involvement
P114 (P114) Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma: randomized, phase 3 KEYNOTE-204 study
T025 (T025) Patient preferences – survey of HL survivors on treatment associated burdens and side effects
T026 (T026) Change in peripheral blood lymphocyte telomere length in relation to mortality and morbidity in Hodgkin Lymphoma patients
T027 (T027) The impact of treatment type and age on ovarian toxicity in the RATHL study
P115 (P115) Osteonecrosis after treatment for Hodgkin lymphoma: The German Hodgkin Study Group (GHSG) experience
P116 (P116) Longitudinal Evaluation of Health-Related Quality of Life (HRQoL) in Hodgkin Lymphoma (HL) Patients and Survivors: Results from the German Hodgkin Study Group (GHSG)
P117 (P117) Breast cancer after Hodgkin lymphoma: influence of endogenous and exogenous gonadal hormones on the radiation dose-response relationship
P118 (P118) Launch of the breast screening after radiotherapy dataset (BARD) – an England wide initiative to improve screening for breast cancer in 9,000 women at high risk following radiotherapy to breast tissue under age 36
P119 (P119) Managed local follow-up of long term lymphoma survivors – the ADAPT programme
P120 (P120) The role of Watch and wait in Nodular Lymphocyte Predominant Hodgkin Lymphoma: single centre data from the modern era
P121 (P121) Neuro-behavioral changes in Hodgkin lymphoma survivors
P122 (P122) Healthcare use among young Hodgkin lymphoma survivors in the era of intensified chemotherapy and limited radiotherapy
P123 (P123) High burden of morbidity from second malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivors
P124 (P124) The Impact of Fertility Preservation on Treatment Delay and Progression-Free Survival in Women with Lymphoma: A Single-center Experience
P125 (P125) Comorbidity assessment using the CIRS in elderly patients with Hodgkin lymphoma: Prediction of Survival
P126 (P126) Risk adapted ABVD based protocol with restricted radiotherapy to bulky disease for Hodgkin Lymphoma (HL): a 20 year follow up multicenter analysis
P127 (P127) Infradiaphragmatic Hodgkin Lymphoma: a large series of patients staged with PET-CT. A particular subset of HL?
P128 (P128) A Retrospective Analysis of Fertility in Female Patients with Advanced Stages of Hodgkin Lymphoma Treated with BEACOPP Escalated Chemotherapy (20 Year Experience of a Single Centre)
P129 (P129) Cause-specific mortality among Hodgkin Lymphoma patients up to 40 years after treatment
P130 (P130) Elderly Hodgkin Lymphoma – Multicenter Retrospective Data Analysis from the Czech Hodgkin Lymphoma Registry
P131 (P131) Incidence of hyperlipoproteinemia in long-term survivors of Hodgkin lymphoma in childhood or adolescence and in healthy controls
P132 (P132) Survivors of adult Hodgkin lymphoma (HL): A frail population. The experience of the survivorship clinic (SC) for adult HL survivors (AHLS) at Istituto Nazionale Tumori of Milan (INT), Italy
P133 (P133) Elderly patients with Classical Hodgkin Lymphoma (CHL) have high rates of secondary B-cell non-Hodgkin Lymphoma (NHL)
P134 (P134) ANALYSIS OF HODGKIN LYMPHOMA (HL) IN OLDER ADULTS IN A SINGLE CENTER
P135 (P135) An update on BETER, the Dutch nationwide survivorship care programme for Hodgkin lymphoma survivors
P136 (P136) Prospective evaluation of pulmonary toxicity in first line treatment of Hodgkin lymphoma patients
P137 (P137) Hodgkin lymphoma and pregnancy – dilemmas of how to treat?
P138 (P138) Second cancer risks in patients with supradiaphragmatic Hodgkin lymphoma
P139 (P139) Prognostic value of clinical, treatment and socio-demographic results of psychological distress among Hodgkin lymphoma survivors in Hungary
P140 (P140) Hodgkin lymphoma in elderly patients – a single center experience
P141 (P141) Are we aware of nutritional status and vitamin D level in Hodgkin lymphoma patients?
P142 (P142) Mental disorders in Hodgkin's disease patients
P143 (P143) Analysis of access time to care for patients with Hodgkin's lymphoma in public hospital in São Paulo
P144 (P144) The use of coping strategies and social skills in young adult patients with Hodgkin’s lymphoma: correlation with anxiety and/or depression symptoms
P145 (P145) Quality-of-life (QoL) outcomes in patients (pts) with classical Hodgkin lymphoma (cHL) treated with nivolumab monotherapy in CheckMate 205 (cohort B), a phase (ph) 2 study
Gürzenich Cologne Martinstraße 29-37 50677 Cologne During the Conference the Secretariat can be contacted at Phone: +49 (0) 173 939 07 30 Email: info@tca-hanke.de
Saturday, October 22, 2016 08:00–18:00 Sunday, October 23, 2016 07:00–18:00 Monday, October 24, 2016 07:00–18:00 Tuesday, October 25, 2016 07:00–18:00
If you are still in need of a hotel room, please contact the conference management: Phone: +49 (0) 2102 669 36 Email: info@tca-hanke.de
Participants are requested to wear their badge at all times during the conference including satellite symposia. A replacement fee will be charged for lost badges.
Complimentary coffee will be served during breaks at the conference. Breakfast and lunch will be available for participants of satellite symposia. There will also be the possibility of buying snacks during the breaks.
A cloakroom is available in the basement.
The conference language is English.
The 10ᵗʰ International Symposium on Hodgkin Lymphoma will be certified by AEKNO with a total of 24 points for the entire meeting. The meeting will be also certified by the European Board for Accreditation in Hematology (formerly EHA) with 24 EBAH credit points. Please collect your certificates before departure at the registration desk (entrance hall of the Gürzenich).
The meeting organizers cannot accept liability of personal injuries sustained or for loss or damage of property belonging to congress participants, either during or as a result of the meeting.
All participants will have free access to High Speed Wireless Internet at the Gürzenich Conference Center at no extra cost. Further details such as access codes will be provided on site. Two internet terminals will be provided allowing internet browsing and access to web based mail.
Pre-registration will close on October 20. All registrations received on or after October 21 will be considered on site registrations and will be charged the on-site fee. Full registration will include access to the scientific sessions and exhibition, a copy of the program and abstract book, welcome reception on Sunday October 23 and all refreshment breaks. Name tags will be issued and will be required at all conference events including satellite symposia. No refund will be possible.
On all the following conference days, the Speakers Ready Room is located on the ground level of the Gürzenich Conference Center next to the registration desk. Speakers are requested to bring their PowerPoint presentations at least 3 hours before their session starts or the day before if the session starts early in the morning. Only Windows PowerPoint les can be accepted. No laptop presentations will be allowed in the session rooms.
There will be a strict non-smoking policy within all areas of the facilities used by the conference.
On Sunday evening the conference will be opened officially. After the Opening Ceremony we invite all participants to our Get Together in the Gürzenich Conference Center. This event will also enable members of the scientific and medical community to get to know their colleagues over a drink and snacks.
Financial support was kindly provided by the Deutsche Forschungsgemeinscha (DFG) within their programme „International Scientific Events“
The Karl Musshoff Stiftung kindly supports the Karl-Musshoff-Price for both, the best basic science abstract and best clinical abstract.
The ONKO-Internetportal in cooperation with Deutsche Krebsgesellschaft e. V. is our media cooperation partner.
Prof. Dr. Andreas Engert Klinik I für Innere Medizin Klinikum der Universität zu Köln Kerpener Str. 62 D-50924 Köln Phone: +49 (0)221-478 5933 Fax: +49 (0)221-478 3778
In accordance with the German Act for Telemedia Services (TMG), § 55 Abs. 2 RStV (section 55, subsection 2 broadcast services state treaty): Prof. Dr. Andreas Engert
Legal Entitiy: The University Hospital of Cologne is a Public Law Institution. Legal Representation: The University Hospital of Cologne is represented by the Board of Directors, in turn represented by: Prof. Dr. Edgar Schömig, CEO and medical director Günter Zwilling, Director of finance Kerpener Str. 62 D-50937 Köln
The Karl Musshoff Foundation was established by Prof. Dr. Karl Musshoff in 1997. The Karl-Musshoff-Prize is granted every three years on the occasion of the ISHL in Cologne for outstanding results in the field of Hodgkin Lymphoma.
The Karl Musshoff Foundation was established by Prof. Dr. Karl Musshoff in 1997. The Karl-Musshoff-Prize is granted every three years on the occasion of the ISHL in Cologne for outstanding results in the field of Hodgkin Lymphoma.